Well, joining us now is CrowdStrike CEO George Kurtz. Crowd Strike is up 42% so far this year. George, it's great to have you back on the show.Welcome. Great to be here. Thank you.So, I'm going to start right there with you. Um, how acute is the risk of cyber security incidents from Iran in the wake of everything we've seen right now. Well, what's important to realize is whenever geopolitical tensions rise, you're going to see a natural increase in cyber attacks.And that's exactly what we've seen. Iran has ...

China Healthcare | Asia Pacific 11th Round of National Drug VBP Around the Corner Key Takeaways Drug selection criteria aims to balance pricing against clinical practice considerations: Among the 75 drugs proposed, 14 drugs will be further evaluated ( Exhibit 1 ), including: 1) five whose generic products have narrower indications approved than the originators' drugs. The reported volume for these drugs may be limited to the scope of commonly-approved indications; 2) nine generics are considered to have rel ...

Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trigger Exercise of up to $7.6 million in Gross Proceeds from 2023 Financing Warrants Tied to FDA Acceptance of NDA for Review PRINCETON, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-sta ...

Core Insights - Cognition Therapeutics, Inc. is advancing zervimesine (CT1812) into a Phase 3 program for mild-to-moderate Alzheimer's disease and has filed for breakthrough therapy designation for dementia with Lewy bodies (DLB) [1][2] Group 1: Clinical Development - An end-of-Phase 2 meeting with the FDA is scheduled for July 9, 2025, to discuss the Phase 2 'SHINE' study results and plans for a Phase 3 program for zervimesine in Alzheimer's disease [1] - The company is also progressing with an expanded access program for zervimesine in DLB, which has garnered high interest from former SHIMMER study participants [3] Group 2: Drug Information - Zervimesine (CT1812) is an investigational oral medication aimed at treating neurodegenerative diseases, specifically Alzheimer's disease and DLB, by potentially interrupting the toxic effects of protein buildup in the brain [4] - The drug has been generally well tolerated in clinical studies to date [4] Group 3: Company Overview - Cognition Therapeutics, Inc. focuses on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and has completed Phase 2 studies for zervimesine in multiple conditions [6]

Core Viewpoint - Cognition Therapeutics, Inc. is advancing its investigational drug zervimesine (CT1812) for the treatment of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB), with an end-of-Phase 2 meeting scheduled with the FDA to discuss Phase 2 study results and plans for a Phase 3 program [1][2][8] Group 1: Clinical Development - The company will hold an end-of-Phase 2 meeting with the FDA on July 9, 2025, to review the Phase 2 'SHINE' study results of zervimesine in Alzheimer's disease [1] - Cognition is also moving forward with plans for a registrational program for DLB based on positive results from the Phase 2 'SHIMMER' study [2] - An expanded access program for zervimesine in DLB is underway, with high interest from former SHIMMER participants [3] Group 2: Drug Information - Zervimesine (CT1812) is an oral, once-daily investigational drug targeting neurodegenerative diseases, specifically Alzheimer's and DLB, by potentially interrupting the toxic effects of harmful proteins in the brain [4] - The drug has been generally well tolerated in clinical studies to date [4] - The USAN Council has adopted zervimesine as the official name for CT1812 [5] Group 3: Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [6] - The company has completed Phase 2 studies for zervimesine in multiple conditions, including DLB and Alzheimer's disease, and is currently conducting an ongoing Phase 2 study in early Alzheimer's disease [6]

3 2 1 ignition and lift. For three nations, a new chapter in space takes flight. God speed.T plus 30 seconds into flight with the Axium 4 crew on board Dragon headed to the International Space Station. ...

The problem was/is not lack of talent.The problem is a future state that contains both of these words while expecting a graceful outcome:▸ "competing"▸ "coordination"Client teams pull this off somewhat because they have to. L2 teams have no obligation to coordinate.venture anthropologist (@0xBalloonLover):ethereum's strategy of punting the roadmap to a bunch of different competing L2 teams only makes sense if there was an abundance of talentbut the talent is pathetic so what's resulted is a bunch of coordin ...

I'd like to get your reaction from what we got over the weekend from Donald Trump air strikes over Iran. I would like to get an idea if you have an appraisal of how imminent the threat from the Iranian nuclear program was. Was it was the American action in violation of international law as a matter of a consequence.Well, the international law says, you know, gives you good to reasons where you can use force. One is self-defense and the other one is by the mandate of the Security Council. So those who use fo ...

Nominal orbital insertion of SpaceX and we add an incredible ride uphill. And now we like set our course for the International Space Station aboard the newest member of the Dragon Fleet, our spacecraft named Grace. Grace is more than a name.It reflects the elegance with which we move through space against the backdrop of Earth. It speaks to the refinement of our mission, the harmony of science and spirit, and the unmmerited favor we carry with humility. Grace reminds us that space flight is not just a feat ...

CogSci 2025论文 投稿 量子位 | 公众号 QbitAI "AI永远无法取代人类"证据-1！ 北大团队最新论文揭示： 人类引以为傲的创造力，如今AI也开始掌握了 。 甚至，研究人员还提出了一种系统性框架，首次从认知科学的角度，对AI模型的组合创造力 （Combinational Creativity） 进行了量化评估 与优化。 结果发现， GPT-4等先进模型 在创意理解任务上已经超越普通人类 （准确率70% vs. 50%） 。 这项研究不仅揭示了当前先进模型理解组合创造力的水平，还提出了一种可计算的方法，显著提升了AI的创意生成能力。 值得一提的是，这篇论文还被认知科学学会年度会议CogSci 2025收录，并被大会选为口头报告（Oral）进行现场讲解。 所以，这到底是咋回事儿呢？ AI开始掌握人类创造力的核心机制 一切起源于这样一个问题： 当AI看到寄居蟹住进易拉罐，它想到了什么？ 因此，要判断AI是否真的"理解"组合创造，就必须建立一个能够揭示其认知路径的系统框架。 用系统性框架量化评估AI的"组合创造力" 一只寄居蟹钻进废弃的易拉罐——这个画面你可能在海滩上见过。大多数人只是一笑而过，但艺 ...